Tesamorelin + Ipamorelin Blend is a research formulation combining Tesamorelin – a stabilized full-length GHRH analogue – with Ipamorelin, a selective ghrelin receptor agonist and growth hormone secretagogue. By simultaneously engaging GHRH receptors and GHSR-1a through these complementary peptides, researchers can study the combined stimulation of both major pituitary GH-releasing pathways in the same experimental system.
Research has independently characterized both components of this blend. Tesamorelin has been studied for its sustained GHRH receptor engagement due to its enhanced metabolic stability compared to native GHRH, generating data on visceral fat distribution, lipid metabolism, and cognitive effects in research contexts. Ipamorelin has been studied for its highly selective GHSR-1a activation with minimal effects on cortisol and prolactin. Research into their combination explores the synergistic potential of engaging both the GHRH and ghrelin receptor axes simultaneously.
Preclinical studies have explored how the Tesamorelin + Ipamorelin combination affects GH peak amplitude, IGF-1 levels, and body composition parameters compared to either compound alone. Research has examined whether Tesamorelin’s sustained GHRH receptor engagement creates a sensitized pituitary environment that amplifies Ipamorelin’s direct GH secretagogue activity. The formulation is a useful research model for studying the coordinated biology of the two primary hypothalamic inputs controlling pituitary GH secretion.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
